Evidence map›Paper›PMID 36077101›Full record

ReviewInternational journal of molecular sciences2022

Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer's Disease Treatment.

Ying Song, Xin-Yi Zhu, Xiao-Min Zhang, He Xiong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Epigenetics in Alzheimer's Disease: A Critical Overview.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ying SongDepartment of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, China.
Xin-Yi ZhuDepartment of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, China.
Xiao-Min ZhangDepartment of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, China.
He XiongDepartment of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, China.
Zhejiang University of Technology · CN

Funding

National Natural Science Foundation of China 82174038Zhejiang Provincial Natural Science Foundation LD22H090002
6 · The paper itself

Abstract

Mitochondrial epigenetic alterations are closely related to Alzheimer's disease (AD), which is described in this review. Reports of the alteration of mitochondrial DNA (mtDNA) methylation in AD demonstrate that the disruption of the dynamic balance of mtDNA methylation and demethylation leads to damage to the mitochondrial electron transport chain and the obstruction of mitochondrial biogenesis, which is the most studied mitochondrial epigenetic change. Mitochondrial noncoding RNA modifications and the post-translational modification of mitochondrial nucleoproteins have been observed in neurodegenerative diseases and related diseases that increase the risk of AD. Although there are still relatively few mitochondrial noncoding RNA modifications and mitochondrial nuclear protein post-translational modifications reported in AD, we have reason to believe that these mitochondrial epigenetic modifications also play an important role in the AD process. This review provides a new research direction for the AD mechanism, starting from mitochondrial epigenetics. Further, this review summarizes therapeutic approaches to targeted mitochondrial epigenetics, which is the first systematic summary of therapeutic approaches in the field, including folic acid supplementation, mitochondrial-targeting antioxidants, and targeted ubiquitin-specific proteases, providing a reference for therapeutic targets for AD.

Indexed as

Alzheimer DiseaseDNA MethylationDNA, MitochondrialEpigenesis, GeneticHumansMitochondrial ProteinsRNA, UntranslatedDNA, MitochondrialMitochondrial ProteinsRNA, UntranslatedAlzheimer’s diseasemethylationmitochondrial DNAmitochondrial epigeneticsnoncoding RNApost-translational modification

Identifiers

PMID36077101
PMCPMC9456144
OpenAlexW4293758667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.